ModifiedPremera BluecrossPolicy N/A

Antidepressants: Pharmacy Medical Necessity Criteria for Brands

Defines when brand-name second-generation antidepressants (SSRI/SNRI and other non‑tricyclic/MAOI antidepressants) are considered medically necessary for members under Premera pharmacy benefits, including criteria for depression and anxiety. Applies to providers requesting pharmacy prior authorization for listed brand drugs.

Policy Summary

PayerPremera Bluecross

PolicyAntidepressants: Pharmacy Medical Necessity Criteria for Brands

Policy CodePolicy N/A

Change TypeMultiple additions, removals, and clarifications

Effective DateMay 1, 2026

Next Review DateN/A

Key ActionRequesters must submit medical records documenting trials and failures of specified generic antidepressants and required clinical documentation to support prior authorization.

SourceLink

POLICY UPDATE CHANGES

Added Exxua (gepirone) coverage criteria for the treatment of depression.

Non-formulary exception review authorizations for all drugs listed in this policy may be approved up to 12 months.

Removed Cymbalta (duloxetine), Forfivo XL (bupropion ER), Symbyax (olanzapine and fluoxetine), and sertraline capsules from the policy because of market removals or generic availability.

Added Raldesy (trazodone oral solution) coverage for the treatment of depression.

Added Auvelity (dextromethorphan and bupropion) coverage criteria for the treatment of depression.

Added brand escitalopram oxalate to policy for the treatment of anxiety and depression.

Removed Remeron (mirtazapine) from the policy.

2generic trial failures typically required

multiplebrand drugs listed as covered with criteria

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Brand Second‑Generation Antidepressants

inv-01: Anxiety disorders - Brand second-generation antidepressants

Covered when ONE of the following trial/failure pathways is met

Anxiety coverage pathways

Two generic SSRIs failed: The individual has had a trial and failure of two generic SSRIs (e.g., citalopram, escitalopram, fluoxetine, paroxetine, sertraline).
Two generic SNRIs failed: The individual has had a trial and failure of two generic SNRIs (e.g., desvenlafaxine, duloxetine, venlafaxine).
One generic SSRI + one generic SNRI failed: The individual has had a trial and failure of one generic SSRI and one generic SNRI.

inv-02: Depressive disorders - Brand second-generation antidepressants

Covered when ALL of the following are met

Depression coverage - generic trial requirement: Brand second-generation antidepressants (including listed brand products such as Auvelity and Exxua when applicable) may be considered medically necessary when the individual has had a trial and failure of two generic second‑generation antidepressants (e.g., fluoxetine, sertraline, venlafaxine, bupropion, mirtazapine).

From policy coverage criteria.

Exxua (gepirone) specific limits: Exxua (gepirone) is medically necessary for depression only after trial and failure of two generic second‑generation antidepressants AND the dose is limited to 72.6 mg per day AND the quantity is limited to 1 tablet per day.72.6 mg/day

From policy coverage criteria.

Raldesy (trazodone oral solution) criteria: Raldesy (trazodone oral solution) is medically necessary when the individual has had a trial and failure of generic trazodone tablet OR documentation is provided that the oral solution is clinically necessary (e.g., trouble swallowing), and the dose is limited to 400 mg per day.400 mg/day

From policy coverage criteria.

inv-03: Policy updates and structural criteria

Policy-level coverage stance and structural notes as present in this section of the document.

Policy structure update: Depression and anxiety criteria were combined into one table; a Length of Approval and Documentation Requirements table were added.

References chunk 21

New drug added: Exxua (gepirone) coverage criteria for the treatment of depression were added to the policy.

References chunk 25

Drugs removed: Cymbalta (duloxetine), Forfivo XL (bupropion ER), Symbyax (olanzapine and fluoxetine), and sertraline capsules were removed from the policy due to market removal or generic availability.

References chunk 27

inv-04: Coverage criteria (historical highlights)

Policy applies coverage for branded SSRIs, SNRIs, and second‑generation antidepressants when specified criteria are met.

Generic trial requirement for Depressive Disorders: Trial and failure of at least two generically available second‑generation antidepressants is required.two generics failed

Documented in 07/14/15 history update

Generic trial requirement for Anxiety Disorders: Trial and failure of at least two generically available SSRIs, or one SSRI and one SNRI, is required.two generics or SSRI+SNRI failed

Documented in 07/14/15 history update

Non‑formulary exception duration: Non‑formulary exception authorizations for listed drugs may be approved for up to 12 months.<=12 months

All other uses of the medications listed in this policy are considered not medically necessary. This policy specifies coverage only for the indications and criteria described for the named brand second‑generation antidepressants; any use outside those specified criteria is classified as not medically necessary.

All other uses of brand SSRI, SNRI, and any second‑generation antidepressant not specified in the policy are considered not medically necessary. The policy was revised to combine depression and anxiety criteria into a single table and to explicitly document that unlisted uses of those branded agents are not covered.

All other uses of brand SSRI, SNRI, and any second‑generation antidepressant not listed in the policy were documented as considered not medically necessary. Historical policy updates expanded indications and then formalized that any use outside the listed criteria is not medically necessary.

Use of the listed medications for indications other than the specified anxiety or depressive disorders criteria is considered not medically necessary. Coverage is restricted to the disorder‑specific criteria (e.g., the anxiety and depressive disorder pathways) and the drug‑specific limits described in the policy.

Use of brand SSRI, SNRI, and any second‑generation antidepressant for indications other than those listed in the policy table is explicitly labeled not medically necessary. The policy notes that brand agents are covered only when the documented criteria for depression or anxiety are met, and all other indications are excluded from coverage.

Uses of brand SSRIs, SNRIs, and other second‑generation antidepressants not specified in the policy were added as not medically necessary. The policy history documents expansions of covered diagnostic categories and subsequent clarifications that any use outside the enumerated depression or anxiety criteria is not medically necessary; the 2020 update combined depression and anxiety criteria and added a table documenting unlisted uses as not medically necessary.

Coding and Dose Limits

Codingmixed

N/A	Coding: N/A

Exxua (gepirone) daily dose limit — 72.6 mg per day

Daily dose limit72.6 mg per day

Quantity limit1 tablet per day

Indication-specific requirementCoverage for Exxua (gepirone) is limited to treatment of depression after trial and failure of two generic second-generation antidepressants

Raldesy (trazodone oral solution) daily dose limit — 400 mg per day

Daily dose limit400 mg per day

Indication requirementRaldesy (trazodone oral solution) is covered for depression after trial and failure of generic trazodone tablet or documentation of clinical necessity for oral solution (e.g., dysphagia)

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization for Branded Antidepressants

Prior authorization is required for branded SSRIs, SNRIs, and second‑generation antidepressants managed through the member's pharmacy benefit. Requests must document required trials of generically available antidepressants per the policy before approval.

Applies to branded agents listed in the policy (see Coverage Criteria).
Managed via the pharmacy benefit; prior authorization edits enforced at point-of-sale.

Step Therapy

Generic‑First Step Therapy Requirements

Step therapy (generic‑first) is enforced: trials of specified generically available antidepressants are required before coverage of brand agents will be approved. For depression, trials and failures of two generic second‑generation antidepressants are required. For anxiety disorders, trials and failures of two generic SSRIs, or one generic SSRI and one generic SNRI, are required.

Depression: trial and failure of two generic second‑generation antidepressants (examples: fluoxetine, sertraline, venlafaxine, bupropion, mirtazapine).

Background and Rationale

Second‑generation antidepressants (including SSRIs, SNRIs and other newer agents) are commonly used for treatment of depression and anxiety. Evidence cited in policy reviews indicates comparable efficacy across many agents; therefore treatment selection should consider side effects, tolerability, patient preference, and cost. This policy applies specifically to single‑source brand second‑generation antidepressants and defines coverage only when the documented disorder‑specific criteria (including required prior trials of generically available agents and drug‑specific limits such as dose or formulation requirements) are met.

Definitions

Second-generation antidepressants

DefinitionAntidepressants developed after tricyclics and MAOIs, including SSRIs, SNRIs and other newer agents; excludes tricyclics and MAOIs.

ExamplesIncludes SSRIs and SNRIs (e.g., fluoxetine, sertraline, venlafaxine) and other newer agents such as vortioxetine and vilazodone.

Policy scopeThis policy applies to single-source brand second-generation antidepressants (brand SSRIs, SNRIs, and other non‑TCA/MAOI agents).

First-line treatment

First-line preferenceInitial treatment of unipolar major depression in adults is generally an SSRI or SNRI per UpToDate and guideline sources reviewed.

Guideline basisUpToDate and guideline reviews support choosing an SSRI or SNRI as initial pharmacotherapy for major depressive disorder.

Initial Therapy and Step Requirements

inv-30: Initial therapy

Initial authorization requirements for brand agents

Initial therapy requirement: Brand second-generation antidepressants are authorized only after required trials and failures of generically available agents per indication (see Depressive and Anxiety criteria).

From Policy Coverage Criteria.

inv-31: Initial therapy guidance

Guideline-based initial therapy preference noted in the review.

First-line preference: Evidence continues to support initial treatment with an SSRI or SNRI rather than other antidepressants for unipolar major depression in adults.

References chunk 23

inv-32: Initial therapy / step requirements

Re-authorization and Continuation Criteria

inv-33: Re-authorization

Re-authorization requirements

Re-authorization: Non-formulary exception reviews may be re‑authorized for up to 12 months if medical necessity criteria are met and chart notes demonstrate continued positive clinical response. All other reviews may be re‑authorized up to 3 years with continued positive response.

From Length of Approval and Re-authorization criteria.

inv-34: Continuation and approval duration

Policy includes continuation/length of approval guidance and documentation requirements added in 2020 and clarified in 2025.

Approval duration: Non‑formulary exception authorizations may be approved for up to 12 months. All other reviews may be approved for up to 3 years when medical necessity criteria are met and chart notes show continued positive clinical response.12 months; up to 3 years

Step Therapy Requirements

Provider action	Policy expectation
Document prior generic trials
Must document prior trials and failures of specified generic agents before authorizing brand therapy — see disorder‑specific requirements (two generics for depression; two SSRIs or two SNRIs or SSRI+SNRI for anxiety).

Scope	Step therapy organization
Depression and anxiety
Depression and anxiety criteria are combined into one table in the policy; step therapy logic (generic‑first trials) is organized within those policy tables. Specific step entries are defined per disorder (see policy tables).

Requirement	Examples / notes
Failure of generics required
Requests for branded agents require failure of specified generic antidepressants prior to approval; for depression this is two generic second‑generation antidepressants, with examples provided in the policy. Failure to document required trials may result in denial.

Quantity Limits and Dosing

Exxua (gepirone) — 1

Quantity limit (tablets)1 tablet per day

DrugExxua (gepirone)

ContextQuantity limit corresponds with dose limit of 72.6 mg/day per policy updates.

Exxua (gepirone) — 72.6 mg

Maximum daily dose72.6 mg

DrugExxua (gepirone)

Policy noteDose limited by 12/01/25 update and reiterated in history entries.

Requirement	Details
Prior trials documented
Must document prior trials and failures of specified generic agents (for depression: trial and failure of two generic second‑generation antidepressants; for anxiety: trial and failure of two generic SSRIs OR two generic SNRIs OR one generic SSRI and one generic SNRI).

Condition	Step therapy requirement
Depressive disorders
Covered when all listed criteria are met; policy combines depression and anxiety criteria into one table and applies step therapy logic within the policy tables (for depression: trial and failure of two generic second‑generation antidepressants).

Requirement	Specified generic failures required
Generic antidepressant trials
Approval of branded second‑generation antidepressants requires documentation of trial and failure of two generic second‑generation antidepressants (examples listed: fluoxetine, sertraline, venlafaxine, bupropion, mirtazapine).